Sanofi

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 16:35:30 13/06/2025 BST			5-day change	1st Jan Change
86.80 ^EUR	-1.00%		-1.82%	-7.40%

05-30	Healthcare Stocks Rise -- Healthcare Roundup	DJ
05-30	Sector Update: Health Care Stocks Advance Late Afternoon	MT

Sanofi, Regeneron Secure US FDA Nod for Kevzara’s Use in Polyarticular Juvenile Idiopathic Arthritis

Published on 11/06/2024 at 15:51, updated on 11/06/2024 at 15:53

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Sanofi

Healthcare Stocks Rise -- Healthcare Roundup	05-30	DJ
Sector Update: Health Care Stocks Advance Late Afternoon	05-30	MT
Top Midday Decliners	05-30	MT
Sector Update: Health Care Stocks Rise in Afternoon Trading	05-30	MT
US Equity Indexes Drop as Trump Lashes Out Against China After Appeals Court Stays Ruling Blocking Import Tariffs	05-30	MT
European shares end May higher as trade uncertainty persists	05-30	RE
European Equities Close Mostly Higher in Friday Trading; German Inflation Rises 2.1% in May	05-30	MT
Regeneron shares slide on mixed trial data for smoker's lung drug	05-30	RE
European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading	05-30	MT
Regeneron shares slide on mixed trial data for smoker's lung drug	05-30	RE
Regeneron Facing Headwinds After 'Underwhelming' Itepekimab Results, Truist Says	05-30	MT
Sector Update: Health Care Stocks Fall Pre-Bell Friday	05-30	MT
Tariffs come and go	05-30
Sector Update: Health Care	05-30	MT
Exchange-Traded Funds Mixed, Equity Futures Lower Pre-Bell Friday Amid US Tariff Reinstatement Decision	05-30	MT
Sanofi, Regeneron Pharmaceuticals Report Mixed Results From 2 Phase 3 Trials of Itepekimab	05-30	MT
Sanofi, Regeneron Respiratory Drug Delivers Mixed Results in Key Trials -- Update	05-30	DJ
SANOFI : UBS reaffirms its Buy rating	05-30	ZD
Foreign companies eye US expansion to lessen fallout from tariffs	05-30	RE
Foreign companies eye US expansion to lessen fallout from tariffs	05-30	RE
European Midday Briefing : Stocks Tick Higher on Positive Inflation Data	05-30	DJ
Sanofi, Regeneron Pharmaceuticals Report Mixed Results From 2 Phase 3 Trials of Itepekimab	05-30	MT
SANOFI : Gets a Neutral rating from JP Morgan	05-30	ZD
Regeneron Pharmaceuticals, Inc. and Sanofi Announces Phase 3 Trial, AERIFY-1, Evaluating the Investigational Use of itepekimab in Adults	05-30	CI
Sanofi: Phase 3 data shared in COPD	05-30	CF

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (79.8%): prescription drugs in the areas of specialty medicine (63.2% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (36.8%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (20.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2024, the group had 52 production sites worldwide. In October 2024, the consumer healthcare products business (Opella) was classified as a discontinued operation. Net sales are distributed geographically as follows: France (4.4%), Europe (17.6%), the United States (48.7%), China (6.5%) and other (22.8%).

Employees

82,878

Sector

Pharmaceuticals

Calendar

06-19 - J.P. Morgan European Healthcare Forum

More about the company